Objective: We aimed to determine whether the ratio of thyrotropin (TSH) to thyroglobulin (Tg) (TSH/Tg) would be able to assist in predicting malignancy in thyroid nodules. Material and Methods: Euthyroid patients operated between the year 2007 and 2014 were retrospectively reviewed. Patients who previously had thyroid disease or surgery and those with increased levels of anti-thyroglobulin antibodies were excluded from this study. Clinicopathological features, as well as serum TSH, Tg, and TSH/Tg were compared between histopathologically benign and malignant groups. Results: Data related to 370 (60.3%) benign and 244 (39.7%) malignant patients were analyzed. The malignant patients exhibited significantly higher TSH, TSH/Tg, and total thyroid volume, and a lower Tg compared to the benign patients (p<0.001 for each). There were 924 (74.2%) benign and 321 (25.8%) malignant nodules. Cytological distribution of the nodules was observed to be as follows: 343 (27.6%) nondiagnostic, 637 (51.2%) benign, 121 (9.7%) atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS), 39 (3.1%) follicular neoplasm/suspicious for follicular neoplasm (FN/SFN), 64 (5.1%) suspicious for malignancy (SM), and 41 (3.3%) malignant. TSH, Tg, and TSH/Tg were significantly different in different Bethesda categories (p<0.001 for each). Median TSH/Tg was the lowest in benign (0.013), and highest in SM (0.054) and malignant (0.086) cytologies. TSH/Tg was significantly higher in the malignant nodules compared to benign nodules, in AUS/FLUS, FN/SFN, and SM categories (p=0.001, p<0.001, and p=0.003, respectively). In the regression analysis, TSH/Tg demonstrated higher diagnostic performance compared to TSH and Tg (p<0.001). Discussion: Preoperative TSH/Tg could be used as a novel marker for differentiating between benign and malignant thyroid nodules. It could also assist in the prediction of risk of malignancy and management decisions when the cytology is indeterminate. 
Introduction
Nodular thyroid disease is the most common thyroid pathology observed in clinical practice. More than 50% of the population has at least one thyroid nodule under ultrasonography examination (1) . Although nodule prevalence is very high, only 5-10% of the nodules are malignant and require surgical and/or medical management (2) . The major concern is to discriminate the malignant lesions from the benign ones, preoperatively. Fine-needle aspiration biopsy (FNAB) for thyroid is the gold standard test used for this purpose. Although it is a rapid, cost-effective, safe, and reliable procedure, the nondiagnostic results requiring re-biopsy and the indeterminate cytology defined as the "gray zone" are the limitations of this method (3, 4) . Atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS), follicular neoplasm or suspicious for follicular neoplasm (FN/SFN), and suspicious of malignancy (SM) categories in the Bethesda classification may be considered indeterminate cytologies. These groups are representative of morphologically abnormal findings that are related to an increased risk of malignancy, though not enough to confirm a malignant lesion (5) . Majority of the nodules with indeterminate cytology are surgically excised due to their malignancy potential, which confronts the patients with risks of morbidity and complications related to unnecessary surgeries (6) . Therefore, it is comprehensible that in addition to cytology, certain other parameters are required to predict malignancy preoperatively. Gender, age, nodule diameter, exposure to radiation, and certain ultrasonography (US) features have been demonstrated to be associated with the risk of malignancy in previous reports (3, 7) . Preoperative high serum thyrotropin (TSH) has also been demonstrated to increase the risk of malignancy in various studies. Boelaert et al. (8) evaluated serum TSH in patients with nodular or diffuse goiter, and observed that even though within normal ranges, high serum TSH was associated with thyroid malignancy. Thyroglobulin (Tg) is a glycoprotein produced specifically in the thyroid follicular cells, regardless of whether they are of malignant or benign nature (9) . It is a well-known marker for persistent or recurrent differentiated thyroid cancer (10) . Although the role of Tg in the postoperative period has been clearly defined, its use as a predictive marker in the preoperative period is debatable (9, 11, 12) . Routine Tg measurement is not recommended as an initial laboratory investigation for thyroid nodules. It is not sensitive or specific for thyroid cancer as it exhibits increased levels in several other thyroid diseases (13) . In the present study, our aim was to evaluate the role of the ratio of TSH to Tg (TSH/Tg) as a novel marker for the prediction of malignant nodules in patients with the euthyroid nodular disease. We also attempted to investigate whether this ratio could be used to predict malignancy in different Bethesda categories and thus, assist in determining the optimal management in case of indeterminate cytology.
Material and Methods
A retrospective analysis of 2,900 patients operated in our center between January 2007 and December 2014 was performed. Since the high anti-thyroglobulin (anti-Tg) levels could cause a confounding effect on absolute Tg, patients with high anti-Tg and the patients without simultaneous measurement of serum anti-Tg were excluded from this analysis. Patients with undetectable preoperative Tg levels (<1 ng/mL) were also excluded from the analysis because this was suggestive of occult antibody interference. Clinical or subclinical hypothyroidism or hyperthyroidism, radiation to head and neck, history of thyroid surgery, and previous or current use of antithyroid or thyroid hormone replacement therapy were the other exclusion criteria. Age, sex, preoperative thyroid functions, antithyroid autoantibodies, US features (thyroid volume, the presence of nodule/nodules, and nodule size and number), and FNAB results were evaluated. Serum TSH, free triiodothyronine (fT3), free thyroxine (fT4), anti-thyroid peroxidase (anti-TPO), and anti-Tg levels were measured using chemiluminescence methods (Immulite 2000, Diagnostic Products Corp., Los Angeles, CA, USA; UniCel Dxl 800, Beckman Coulter, Brea, CA). The normal levels for TSH, fT3, and fT4 were 0.4-4 µIU/mL, 1.57-4.71 pg/mL, and 0.85-1.78 ng/dL, respectively. Anti-TPO levels higher than 35 IU/mL, and anti-Tg levels higher than 40 IU/mL were considered positive. The normal range for Tg was 0-78 ng/mL. The three diameters obtained from thyroid ultrasonography (maximal length × width × depth) were multiplied with π/6 to calculate the volume of each lobe, and the sum of volumes of the two lobes was defined as the thyroid volume. US (GE (82.8%) of the SM, and 41 (100%) of the malignant cytology (Table 3) . In all Bethesda categories, mean fT3 was similar in histopathologically benign and malignant nodules. In the nodules with preoperative nondiagnostic and AUS/FLUS cytology, mean fT4 was higher in malignant nodules compared to benign nodules (p=0.017 and p=0.019, respectively). Benign and malignant nodules presented similar median TSH when the Bethesda categories were considered separately, except in the nondiagnostic category where malignant nodules demonstrated higher median TSH compared to the benign ones (1.2 µIU/mL vs. 1.0 µIU/mL; p=0.012). Median Tg was significantly higher in histopathologically benign nodules compared to malignant nodules in AUS/FLUS, FN/SFN, and SM cytology (p=0.001, p<0.001, and p=0.002, respectively). Median TSH/Tg was significantly lower in benign nodules compared to malignant nodules in AUS/FLUS, FN/SFN, and SM categories (p=0.001, p<0.001, and p=0.003, respectively). Benign and malignant nodules demonstrated similar TSH/Tg in the nondiagnostic and benign Bethesda categories (p=0.347 and p=0.580, respectively). These significant and nonsignificant results for each Bethesda category were also valid for Tg/TSH, however, with inverse relations (Table 3) . Variables associated with malignancy were examined by multiple logistic regression analysis model (Table 4) . In Model I, the presence of Hashimoto thyroiditis, total thyroid volume, TSH, and Tg were included as variables. In addition to the variables of Model I, TSH/Tg and Tg/TSH were included in Model II and III, respectively. Total thyroid volume (OR=1.045; p<0.001) and serum TSH (OR=1.260; p=0.043) were identified as independent predictors for malignancy in Model I. Every 1 mL increase in the volume and every 1 µIU/mL increase in TSH was associated with 1.045 and 1.260 times increased risk of malignancy, respectively. In Model II, total thyroid volume (OR=1.035; p<0.001) and TSH/Tg (x100) (OR=1.162; p<0.001) were identified as independent predictors for malignancy. Malignancy risk increased by 1.162 times for every 1% increase in TSH/Tg. In Model III, total thyroid volume (OR=1.035; p<0.001) and Tg/TSH (x100) (OR=0.993; p<0.001) were identified as independent predictors for malignancy, and a 1% decrease in Tg/TSH was associated with 1 
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The analysis was made with 1245 nodules. Numerical variables are shown as mean ± standard deviation or median (min-max). The diagnostic performance of total thyroid volume, TSH, Tg, TSH/Tg, and Tg/TSH for the prediction of malignancy was evaluated using ROC curve analysis. TSH/Tg and Tg/TSH demonstrated similar diagnostic performance, which was higher than that of total thyroid volume, TSH, and Tg (p<0.001). In addition, the diagnostic performance of total thyroid volume was higher than that of TSH and Tg (p<0.001) ( Figure  1) . A cut-off value of >0.03 for TSH/Tg could predict malignancy with 61.9% sensitivity and 74.1% specificity. A Tg/TSH value of ≤25.85 also demonstrated 61.1% sensitivity and 76.8% specificity in predicting malignancy.
Discussion
Clinical follow-up is sufficient for most of the thyroid nodules after the clinical or cytological exclusion of malignancy. The major concern is to identify malignant lesions preoperatively. Detecting the minority of thyroid cancer patients is a great challenge for the clinician (14) . Various risk factors that might assist in predicting malignancy in thyroid nodules have been investigated to date. High serum TSH is one of those risk factors. TSH plays an important role in the regulation of thyroid differentiation genes, growth factors, and receptors (15) . Mitogenic effect of TSH on thyroid carcinoma cells has been well described previously (16, 17) . Varying levels of TSH-receptor mRNA are expressed in nearly all papillary and follicular carcinomas (18) . Increasing serum TSH levels, although within normal limits, have been reported to be associated with a higher risk of malignancy in patients with thyroid nodules (8, 19) . Shi et al. (14) demonstrated that the prevalence of differentiated thyroid cancer (DTC) increased significantly as the serum TSH levels increased. A serum TSH level of 1.9-4.8 mIU/L and a serum TSH level >4.8 mIU/L were observed to be associated with 1.57 (95% CI: 1.03-2.40; p=0.038) times and 5.71 (95% CI: 2.31-14.14; p=0.0002) times of the likelihood of malignancy, respectively, compared to a serum TSH level 
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of 1.0-1.9 mIU/L. Higher TSH has also been observed to be associated with an increased risk of lymph node metastasis and an advanced disease stage (14) . Another study suggested an association between higher serum TSH and significantly increased risk of DTC. The risk of malignancy increased by 25% when the TSH levels were in the range of 0.40-1.39 mIU/L, while the increase was 35% when the TSH levels were in the range of 1.40-4.99 mIU/L (p=0.002) (20) . Similar to these findings, we also observed higher serum TSH (within normal ranges) in histopathologically malignant patients compared to benign patients. In contrast to these findings, Kim et al. (21) reported similar serum TSH levels in both papillary thyroid cancer (PTC) and benign nodules. There are also additional studies that reported lack of association between TSH and malignancy (6, 22) . Tg is closely associated with the synthesis and deposition of thyroid hormones, and small amounts of physiological Tg are released into peripheral circulation in healthy people. Detection of Tg in serum after total thyroidectomy in patients with DTC is suggestive of recurrent or persistent disease (23) . Unlike the setting of postoperative cancer follow-up, the use of Tg in the preoperative assessment of thyroid nodules is debatable (12). Guarino et al. (24) did not find any diagnostic or prognostic value of preoperative Tg measurement in thyroid nodules. Another study examining the role of preoperative Tg, in addition to the US features, in predicting malignancy in thyroid nodules demonstrated that it could not be used for differentiating malignant nodules from the benign ones. The authors concluded that the only predictive factors for malignancy were suspicious US features (25) . On the contrary, there exist studies which suggest a possible role of Tg in the preoperative diagnosis of malignancy (26, 27) . However, Tg measurement
is not yet a recommended laboratory examination during the preoperative assessment of thyroid nodules (13) .
In the present study, we observed that both TSH and Tg were risk factors for malignancy in euthyroid patients with thyroid nodules. The other risk factors determined were as follows: the presence of Hashimoto thyroiditis, increased total thyroid volume, increased TSH/Tg and decreased Tg/TSH. However, the diagnostic value of total thyroid volume was higher than that of serum TSH and Tg. In the regression analysis, total thyroid volume, TSH, TSH/Tg, and Tg/TSH were identified as independent predictors of malignancy. ROC curve analysis demonstrated that both TSH/Tg and Tg/TSH were better predictors compared to the other risk factors. As confirmed in the present study, TSH/Tg appears to be one of the promising thyroid malignancy markers under investigation. Wang et al. (28) evaluated TSH/Tg in 158 benign and 242 malignant nodules, and suggested that a high preoperative serum TSH/Tg was a risk factor for thyroid cancer and that TSH/Tg correlated with malignancy better than serum TSH. Sensitivity and specificity of TSH/Tg for prediction of malignancy were 74.3% and 61.5%, respectively, in patients with normal anti-Tg levels. In the mentioned study, however, patients with positive anti-Tg and patients with Tg non-producing and TSH unresponsive tumors, such as medullary and anaplastic cancer, were not excluded from the analysis. In another study including 134 benign and 68 malignant patients, preoperative TSH and Tg were not useful in detecting thyroid cancer, and although TSH/Tg was obtained as a predictor for malignancy in the univariate analysis, it did not remain statistically significant in the multivariate analysis. Patients on antithyroid or thyroid hormone replacement therapy, along with one patient with thyroid metastasis from renal cell carcinoma, were also included in the mentioned study (29) . In comparison with the previous two studies, the sample size was higher and the study population was more uniform in our study. Similar to the report by Wang et al. (28), both TSH and TSH/Tg were obtained as predictors for malignancy in the present study, and TSH/Tg was observed to be superior to TSH. The risk of malignancy and recommended clinical management have been described for each category in The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) (30) . A benign cytology accurately predicts a benign nodule that can be followed-up, while a malignant cytology carries a 97-99% risk of cancer, requiring thyroidectomy. AUS/FLUS, FN/SFN, and SM categories are cytologically indeterminate groups that present a 5-15%, 15-30%, and 60-75% risk of malignancy, respectively. In these categories, the samples are adequate for cytological evaluation and abnormal morphological findings are also observed, which are, however, not enough to confirm malignancy (31 There were certain limitations in our study. We attempted to conduct a uniform group study, however, while doing that, a selection bias might have occurred inherently. The ratio of histopathologically confirmed malignant nodules was higher than expected in all the Bethesda categories. Our center is one of the biggest tertiary referral centers in our country, and a considerable number of patients with high suspicion of malignancy are referred from other centers. Another limitation was that the number of nodules was low in certain Bethesda categories. We are aware that patients with multiple nodules might have dominated the findings, particularly TSH/Tg and Tg/TSH, in the module-based analysis. In such patients, the nodule exhibiting highest malignancy potential in the cytological examination might have been chosen instead of including each nodule separately in the analysis. However, this approach would lead to consideration of only the nodule with the highest risk of malignancy and the other nodules would not be represented. In general practice, when cytology is benign, thyroidectomy is suggested as an option only in case of large lesions or indeterminate results such as follicular neoplasm. This might partly explain the higher Tg levels in the histopathologically benign group. Lastly, we included only euthyroid patients in our study. This may also be considered a strong aspect of our study. However, from another perspective, patients with normal TSH, fT3, and fT4 displaying hot nodules in scintigraphy might exhibit lower TSH than the patients displaying warm or cold nodules. We could not exclude this possibility as we did not perform thyroid scintigraphy.
Conclusion
High serum TSH, even within normal ranges, was observed to be associated with an increased risk of thyroid malignancy. However, TSH/Tg proved to be a better predictor of malignancy compared to TSH or the other risk factors identified in this study. TSH/Tg could serve as a novel, cost-effective, practical, and applicable index for risk stratification of thyroid nodules, and when combined with other factors, it could assist clinicians in forming important decisions regarding the management of nodules. Further prospective and large-scale research are required to support these findings. Ethics: Ethics Committee Approval and Informed Consent: Ethical review board of Yıldırım Beyazıt University Ataturk Training and Research Hospital approved the study protocol. Source of Finance: During this study, no financial or spiritual support was received neither from any pharmaceutical company that has a direct connection with the research subject, nor from a company that provides or produces medical instruments and materials which may negatively affect the evaluation process of this study.
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